Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-20
2007-02-20
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S364000
Reexamination Certificate
active
10864698
ABSTRACT:
Bicyclic indolyl derivatives and compositions containing such compounds are disclosed. Methods of using the bicyclic indolyl derivatives and compositions containing such composition as serotonergic agents, such as in the treatment of depression and anxiety, are also disclosed. In addition, processes for the preparation of bicyclic indolyl derivatives are disclosed.
REFERENCES:
patent: 5723464 (1998-03-01), Brightwell et al.
patent: 0 372 657 (1990-06-01), None
patent: 0 395 312 (1990-10-01), None
patent: 0 512 755 (1992-11-01), None
patent: 0 737 678 (1996-10-01), None
patent: WO 95/33743 (1995-12-01), None
Jones et al, Pharmacology, Biochemistry and Behavior, vol. 71, p. 555-568 (2002).
Schechter et al. Current Pharmaceutical Design, vol. 8, p. 139-145 (2002).
Patat et al. Clinical Pharmacology & Therapeutics, vol. 77, p. P29. (2005).
Pedigo et al., “Discrimation of Multiple [3H]5-Hydroxytryptamine Binding Sites by the Neuroleptic Spiperone in Rat Brain,”J. Neurochem. 1981, 36, 220.
Fargin et al., “The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1Areceptor,”Nature1988, 335, 358.
K. Rasmussen and V. P. Rocco, “Recent Progress in Serotonin (5-HT)1AReceptor Modulators,”Annual Reports in Medicinal Chemistry, vol. 30, J. A. Bristol, ed., 1-9 (1995).
L. E. Schechter and M. G. Kelly, “An Overview of 5-HT1AReceptor Antagonists: Historical Perspective and Therapeutic Targets,”Current Drugs Serotonin ID Research Alert1997, 2, 299-309.
Bundgaard, et al.,Journal of Drug Delivery Reviews1992, 8, 1-38.
D. J. Bill and A. Fletcher, “Correlation of in vivo functional and anxiolytic effects of 5-HT1Areceptor ligands in the mouse,”Br. J. Pharmacol. 1994, 111, 151P.
Krogsgaard-Larsen, et al., (ed.),Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991).
Bundgaard, “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”Journal of Pharmaceutical Sciences1988, 77, 285.
J-L. Moreau, et al., “Behavioral Profile of the 5-HT1AReceptor Antagonist (S)-UH-301 in Rodents and Monkeys,”Brain Res. Bull. 1992, 29, 901.
R. J. Rodgers and J. C. Cole, “Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1Areceptor antagonist, in the murine elevated plus-maze test,”Eur. J. Pharmacol. 1994, 261, 321-325.
J. F. Deakin, et al., “Clinical implication of microdialysis findings,”Trends Pharmacol. Sci., 1993, 14, 263.
S. Hjorth and S. B. Auerbach, 5-HT1Aautoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI),Behav. Brain Res. 1996, 73, 281-283.
Schechter et al., “Serotonergic antidepressants: Current and future perspectives,”Current Opinion in CPNS Investigational Drugs1999, 1, 432-447.
T. Hashimoto, et al., “Increase in serotonin 5-HT1Areceptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia,”Life Sci., 1991, 48, 355-363.
J. N. Joyce, et al., “Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics,”Neuropsychopharmacol. 1993, 8, 315-336.
P. W. J. Burnet, et al., “5-HT1A and5-HT2AReceptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia,”Neuropsychopharmacol., 1996, 15(5), 442-455.
H. Y. Meltzer, “Role of Serotonin in the Action of Atypical Antipsychotic Drugs,”Clin. Neurosci. 1995, 3, 64-75.
M. Hamon, et al., “Alterations of Central Serotonin and Dopamine Turnover in Rats Treated with Isapirone and Other 5-Hydroxytryptamine1AAgonists with Potential Anxiolytic Properties,”J. Pharmacol. Exp. Ther. 1988, 246(2), 745-752.
L. E. Schechter, et al., “Alterations of Central Serotoninergic and Dopaminergic Neurotransmission in Rats Chronically Treated with Ipsapirone: Biochemical and Electrophysiological Studies,”J. Pharmacol. Exp. Ther. 1990, 255, 1335-1347.
K. Q. Do, et al., γ-Glutamylglutamine and Taurine Concentrations Are Decreased in the Cerebrospinal Fluid of Drug-Naïve Patients with Schizophrenic Disorders,J. Neurochem. 1995, 65, 2652-2662.
G. C. Tsai, et al., “Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains,”Arch. Gen. Psychiatry1995, 52, 829-36.
Schechter et al., “The Potential Utility of 5-HT1AReceptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimer's Disease,”Current Pharmaceutical Design2002, 8, 139-145.
Harder et al., The 5-HT1Aantagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transaction in the marmoset,Psychopharmacol. 1996, 127, 245-254.
Carli et al, “(S)-WAY 100135, a 5-HT1Areceptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine,”Eur. J. Pharmacol. 1995, 283, 133-139.
Harder et al., “The 5-HT1Aantagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys,”Neuropharmacology, 2002, 39, 547-552.
P. T. Francis, et al.,Neurotransmitters and Neuropeptides in Alzheimer's Disease, R. D. Terry, ed., Raven Press, Ltd., New York, 247-261 (1994).
U. Staubli, et al., “Facilitation of glutamate receptors enhances memory,”PNAS(USA) 1994, 91, 777-781.
R. G. Morris, et al., “Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist,”Nature1986, 319, 774-776.
T. V. Bliss and G. L. Collinridge, “A synaptic model of memory: long-term potentiation in the hippocampus,”Nature1993, 361, 31-39.
J. T. Greenmyre, “The Role of Glutamate in Neurotransmission and in Neurologic Disease,”Arch. Neurol.1986, 43, 1058-1063.
W. F. Maragos, et al., “Glutamate dysfunction in Alzheimer's disease: an hypothesis,”Trends Neurosci.1987, 10, 65-8.
B. T. Hyman, et al., “Alzheimers's Disease: Glutamate Depletion in the Hippocampal Perforant Pathway Zone,”Ann. Neurol.1987, 22, 37-40.
N. W. Kowall and M. F. Beal, Glutamate-, Glutaminase-, and Taurine- immunreactive Neurons Develop Neurofibrillary Tangles in Alzheimer's Disease,Ann. Neurol.1991, 29, 162-167.
D. M. Bowen, et al., Neurotransmission—the link integrating Alzheimer research?Trends Neurosci.1994, 17, 149-150.
S. N, Dijk, et al., “NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurons: evidence for modulation by a 5-HT1Aantagonist,”Br. J. Pharmacol.1995, 115, 1169-74.
R. Araneda and R. Andrade, “5-Hydroxytryptamine2and 5-Hydroxytryptamine1Areceptors mediate opposing responses on membrane excitability in rat association cortex,”Neuroscience1991, 40, 399-412.
D. M. McLoughlin, et al., “Central Serotonergic Hyperresponsivity in Late-Onset Alzheimer's Disease,”Am. J. Psychiatry1994, 151, 1701-3.
J. D. Buxbaum, et al., “Protein phosphorylation inhibits production of Alzheimer amyloid β /A4 peptide,”PNAS(USA), 1993, 90, 9195-8.
N. Sakai and C. Tanaka, “Inhibitory modulation of long-term potentiation via the 5-HT1Areceptor in slices of the rat hippocampal dentate gyrus,”Brain Res.1993, 613, 326-30.
K. Briner and R. C. Dodel, “New Approaches to Rapid Onset Antidepressants,”Cur. Pharm. Des.1998, 4(4), 291-302 plus Erratum.
M. B. Tome, et al., “Paroxetine and pindolol: a randomized trial of serotonergic autorecptor blockade in the reduction of antidepressant latency,”Int. Clin. Psy.1997, 12, 81-9.
V. Perez, et al., Randomised, double-blind, placebo-controlled trial of pindalol in combination with fluoxetine antidepressant treatment,Lancet1997, 349, 1594-7.
P. A. Abrahamsson, et al., “Peptide-Hormone- and Serotonin-Immunoreactive Cells in Normal and Hyperplastic Prostate Glands,”Pathol. Res. Pract.1986, 181, 675-683.
N. M. Hoosein, et al., Expression
Bravo Byron A.
Childers Wayne E.
Harrison Boyd L.
Kelly Michael G.
Schechter Lee E.
Bernhardt Emily
Woodcock & Washburn LLP
Wyeth
LandOfFree
Bicyclic indolyl derivatives and methods for their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic indolyl derivatives and methods for their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic indolyl derivatives and methods for their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3881308